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Although prospective, our study reports a single-center
experience in a small and highly selected patient cohort with a
remarkably low-risk profile and a very short time-to-treatment.
There is a conflicting evidence about the prognostic significance
of prodromal angina associated with pPCI, because someone
found a better outcome (7), while others not (8,9). We
documented that the additional infarct size reduction associated
with prodromal angina translated into better long-term ejection
fraction, which could positively affect prognosis in an appropri-
ately sized patient cohort. Differences in patient selection and
study protocols (retrospective vs. prospective), as well as incon-
sistency of the prodromal angina definition, could also explain
conflicting results.
In conclusion, in our study, prodromal angina leads to a smaller
infarct size most likely through ischemic preconditioning. This
might represent a clinical “marker” of myocardial viability. Larger
prospective trials are needed to demonstrate whether this obser-
vation translates into a better outcome in patients receiving pPCI.
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Gender Differences in Endothelial Tissue-Type Plasminogen Activator Release
in Middle-Aged Adults
To the Editor: Between the ages of 45 and 65 years, the incidence
of myocardial infarction is three times higher in men compared
with women. In addition, the prevalence of thrombotic stroke is
50% greater in men than women (1). The mechanisms behind
this gender difference in atherothrombotic events remain unclear.
Impaired endothelial regulation of fibrinolysis, specifically reduced
capacity to release tissue-type plasminogen activator (t-PA), has
been linked directly to increased atheromatous plaque burden and
increased coronary atherothrombosis (2,3). Endothelial t-PA re-
lease is the predominant physiologic mechanism governing endog-
enous fibrinolysis. Currently, it is unknown if a gender difference
in endothelial t-PA release exists. If so, this may contribute to the
gender-related disparity in the prevalence and incidence of athero-
thrombotic events in middle-aged adults. We tested the hypothesis
that the capacity of the endothelium to release t-PA is greater in
middle-aged women compared with men.
Sixty-six healthy sedentary adult humans ages 45 to 65 years
were studied: 30 men (58  1 year) and 36 women (58  1 year).
All subjects were nonobese (body mass index 30 kg/m2), nor-
motensive (blood pressure 140/90 mm Hg), nonsmokers, non-
medicated, and free of overt cardiovascular, metabolic, and hema-
tologic disease, which were assessed by medical history, resting and
exercise electrocardiograms, and fasting blood chemistries. The
women were at least one year postmenopausal (range 1 to 32 years)
and had never taken or had discontinued use of hormone replace-
ment therapy at least one year before the start of the study. Before
participation, the subjects provided written informed consent
according to the guidelines of the University of Colorado at
Boulder.
Endothelial release of t-PA antigen and plasminogen activator
inhibitor (PAI)-1 antigen in response to bradykinin and sodium
nitroprusside was determined using an isolated forearm model.
Net release or uptake rates were calculated as follows: net release
(CV  CA)  (FBF  [101  hematocrit/100]), where CV and
CA represent the concentration in the vein and artery, respectively,
and FBF represents forearm blood flow. The total amount of t-PA
antigen released across the forearm in response to bradykinin was
calculated as the area under each curve above baseline using a
trapezoidal model. Bradykinin was infused intra-arterially at 12.5,
25, and 50 ng/100 ml tissue/min and sodium nitroprusside at 1, 2,
and 4 g/100 ml tissue/min for 5 min at each dose. To avoid an
order effect, the sequence of drug administration was randomized.
Plasma concentrations of t-PA and PAI-1 antigen were deter-
mined by enzyme immunoassay.
Differences in subject baseline characteristics and area under the
curve data were determined by unpaired t test. Group differences in
FBF and endothelial t-PA and PAI-1 release to bradykinin and
sodium nitroprusside were determined by repeated measures anal-
ysis of variance. The relationships among the variables of interest
were assessed by means of Pearson’s correlation coefficient and
linear regression analysis. Data are reported as mean  SEM.
Statistical significance was set at p  0.05.
Although none of the subjects was obese, the men demonstrated
higher (all p  0.05) body mass (81.8  1.5 kg vs. 65.4  1.6 kg),
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body mass index (26.1  0.5 kg/m2 vs. 24.4  0.6 kg/m2), and
waist circumference (94.1  1.7 cm vs. 83.2  2.1 cm), whereas
the women had a higher percentage of body fat (35.7  1.1% vs.
25.8  0.5%). The FBF responses to bradykinin and sodium
nitroprusside were modestly (15%) but significantly higher in the
men.
Basal net release of t-PA antigen was not significantly different
between the groups. In response to bradykinin, net release of t-PA
antigen increased in a dose-dependent fashion in both groups;
however, the response was significantly greater in the women
(from 0.9  0.6 ng/100 ml tissue/min to 72.6  5.3 ng/100 ml
tissue/min) compared with the men (0.9  0.6 ng/100 ml
tissue/min to 45.7  3.3 ng/100 ml tissue/min). As a result, the
total amount of t-PA antigen released (area under the curve) was
46% higher (p  0.01) in the women than the men (344  27
ng/100 ml tissue vs. 235  20 ng/100 ml of tissue) (Fig. 1).
Sodium nitroprusside elicited no significant changes in endothelial
t-PA antigen release in either group. The effects of bradykinin and
sodium nitroprusside on the net release of PAI-1 antigen were
minimal and not significantly different between groups. No sig-
nificant correlation was found between any anthropometric or
metabolic variable and t-PA release in either group.
The primary new finding of the present investigation is that
endothelial release of t-PA occurs in a gender-specific fashion in
healthy middle-aged adults. Indeed, the rate and total amount of
t-PA released from the endothelium were 50% higher in
middle-aged women compared with men. Our findings demon-
strate a major gender-related difference in an important endoge-
nous defense mechanism against thrombosis.
The reasons for the overwhelming gender disparity in cardio-
vascular disease rates in middle-aged adults are unclear. Scrutiny of
epidemiologic data indicates no significant gender-related differ-
ences in the incidence and prevalence of traditional cardiovascular
disease risk factors in middle-aged adults (1). To the best of our
knowledge, this study is the first to demonstrate gender-specific
differences in the capacity of the endothelium to release t-PA in
middle-aged adults. Endothelial release of t-PA is the crucial step
in the prevention of clot propagation and plays a central role in
maintaining vascular patency. Importantly, diminished t-PA re-
lease is associated with atherosclerotic disease and clinical cardio-
vascular events (2–5). Given the lack of appreciable gender
discrepancy in other important risk factors, the observed difference
in endothelial t-PA release may be a function of intrinsic genetic
phenotypes between men and women. Indeed, there is evidence
linking specific genetic expression profiles with gender differences
in arterial stiffness (6). We are currently exploring potential
gender-related differences in polymorphisms associated with t-PA
release.
Although the men demonstrated greater vasodilator capacity
than the women, we do not believe that the difference (15%) is
physiologically or clinically remarkable. What the FBF responses
clearly indicate is that the noted gender difference in t-PA release
was not a blood flow-related phenomenon. Despite higher FBF
responses to bradykinin, the men exhibited lower endothelial
release of t-PA than women. More importantly, when viewed
collectively the divergent vasomotor and fibrinolytic responses
highlight the complexities of gender-related differences in vascular
function that, in turn, impact disease development.
In conclusion, the results of the present study identify a marked
difference in the capacity of the endothelium to acutely release
t-PA between middle-aged men and women. Endothelial fibrino-
lytic function may be an important physiologic mechanism under-
lying the profound gender-related difference in the incidence and
prevalence of atherothrombotic events in middle-aged adults.
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Letters to the Editor
Is There an Optimal
Hematocrit Value for Cardiac Patients?
The significance of anemia in congestive heart failure (CHF) has
only recently received attention, as evidenced by two state-of-the-
art papers published over the last several months (1,2). Anemia is
more common in CHF than could be accounted for by age or the
degree of renal dysfunction (2). Moderate to severe anemia can
contribute to the development or worsening of CHF. Conversely,
CHF can lead to moderate anemia (2). Recent reports have largely
resolved the question: Is anemia a cause or a consequence of CHF?
(3). Erythropoietin, which has a long history in the management of
anemia complicating chronic renal failure, is being used for
treatment of anemia in CHF (4–6).
Besides the potential risks of worsening hypertension and
increased thrombosis as pointed out by Felker et al. (1), anemia
correction in CHF may have other adverse effects. High hemato-
crit has been reported to be associated with a higher rate of Q-wave
myocardial infarction (MI) after coronary artery bypass grafting
(7). That a high hematocrit value was associated with an increased
risk for MI has actually been known for a long time (8). As a
matter of fact, George Burch (9–14), who wrote extensively on the
subject since the early 1960s, advocated bloodletting in patients
with coronary artery disease with a high hematocrit value (13,14).
It might be appropriate to quote what Burch wrote in 1979 (14):
“It is well known that a high hematocrit is associated with
high viscosity and that a highly viscous fluid requires more
work of the pump to circulate it than does a less viscous
liquid. Furthermore, the flow of highly viscous fluid is
reduced, even with all else being equal. Nevertheless, phy-
sicians fail to bleed patients with active coronary disease and
myocardial ischemia, whose hematocrit is high and whose
blood viscosity is increased. It has been shown that blood-
letting in patients with ischemic heart disease definitely
improved the clinical state of these patients when their
hematocrit was reduced to average normal levels.”
Therefore, as Felker et al. (1) cautioned, one must balance the risk
of correcting the anemia in CHF against the risks of such
treatment. What the optimal hematocrit value should be for
patients with coronary artery disease or CHF has to await the
results of controlled studies on a large number of patients.
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Further Aspects of Anemia,
Heart Failure, and Erythropoietin
A routine laboratory hemoglobin measurement reflects “hemoglo-
bin concentration.” This approximates the total-body circulating
hemoglobin (TBH) to plasma volume (PV) ratio, but provides no
absolute quantitative information about either TBH or PV. Ane-
mia arises when the TBH:PV ratio falls. This occurs with either
decreased TBH or increased PV. This distinction is important: in a
recent study, 46% of anemic patients with heart failure had a normal
total red cell volume, with anemia attributable to excess PV (1).
In their review, Felker et al. (2) raise several issues concerning
anemia and heart failure that warrant further consideration. They
adopt the term “true anemia” to describe a decrease in TBH (2).
This begs the question: is a reduced hemoglobin concentration any
truer if it arises from decreased TBH rather than increased PV?
Undoubtedly not, and the term “true anemia” should probably be
avoided as it is imprecise. Felker et al. also indicate that “anemia
results in decreased oxygen-carrying capacity” (2). Again, this
statement is imprecise. It is a decrease in TBH that results in
decreased oxygen-carrying capacity.
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